STLR-201
Sjogren's syndrome-related dry eye disease
Pre-clinicalActive
Key Facts
Indication
Sjogren's syndrome-related dry eye disease
Phase
Pre-clinical
Status
Active
Company
About Stellular Bio
Stellular Bio is developing an off-the-shelf, platelet-derived biologic therapy targeting the large and growing market for ocular surface diseases. The company's PRB platform seeks to combine the polypharmacology of platelet-rich plasma with the consistency and scalability of an engineered product. With a Series 1 financing round closed and a leadership team experienced in biotech development and manufacturing, Stellular is positioned to advance its lead candidate into clinical trials. The initial focus is on severe dry eye disease, with plans to expand into broader OSD indications.
View full company profile